On September 6, 2022 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported the publication of abstracts reporting clinical data and trial design for tumor infiltrating lymphocyte (TIL) cell therapies at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2022 in Paris, France, September 9 – 13, 2022 (Press release, Iovance Biotherapeutics, SEP 6, 2022, View Source [SID1234619022]). The details of the abstracts, which are available on Iovance.com, are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract #844P: Efficacy and safety of lifileucel, an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 antibody
Presentation Type: Poster
Authors: James Larkin, et al.
Date: Saturday, September 10, 2022, 9 a.m. CET to 5 p.m. CET, Hall 4

Abstract #883TiP: A phase 1/2 open-label study (IOV-GM1-201) of TALEN-mediated PD-1 inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC
Presentation Type: Trial in Progress (TiP) Poster
Authors: Jason Chesney, et al.
Date: Saturday, September 10, 2022, 9 a.m. CET to 5 p.m. CET, Hall 4

On September 6, 2022 Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, reported that Chief Executive Officer Piers Ingram, Ph.D., and Chief Financial Officer Josh House will participate in one-on-one investor meetings at Morgan Stanley’s 20th Annual Global Healthcare Conference (September 12-14, 2022), held at the Sheraton New York Hotel in New York City (Press release, Hummingbird Bioscience, SEP 6, 2022, View Source [SID1234619021]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 6, 2022 Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, reported that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 4:30 p.m. E.T (Press release, Galera Therapeutics, SEP 6, 2022, View Source [SID1234619020]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be accessible from the Investors page of Galera’s website, investors.galeratx.com. An archived version of the webcast will be available in the Events & Presentations section of the Investors page of Galera’s website for 30 days following the event.

On September 6, 2022 G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, reported that the Company will host a virtual R&D Day, "Innovations in Oncology: The Science of Trilaciclib", on Thursday, September 15, 2022, from 9:00 a.m. to 11:00 a.m. ET (Press release, G1 Therapeutics, SEP 6, 2022, View Source [SID1234619019]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

G1 will review the development and expansion strategy for trilaciclib, its innovative investigational therapy to improve the lives and outcomes of people living with cancer. The Company will also present new preclinical data supporting potential of trilaciclib to work synergistically with other anti-cancer therapies. Trilaciclib is currently in clinical trials assessing its myeloprotective and anti-tumor immunomodulatory effects in a range of tumor types and in combination with a variety of treatments, including ADCs and checkpoint inhibitors.

Additionally, the program will feature insights from leading clinicians on the differentiated and broadly applicable immune-based mechanism of action of trilaciclib; the importance of transient CDK4/6 inhibition; and the urgent need to improve treatment options for patients with colorectal cancer:

Shom Goel, B Med Sci, MBBS, FRACP, PhD, Peter MacCallum Cancer Centre, The University of Melbourne
Richard Goldberg, MD, Professor Emeritus and former Director, West Virginia University Cancer Institute (WVUCI)
A webcast of the event can be accessed on the Events & Presentations page of www.g1therapeutics.com. The webcast will be archived on the same page for 90 days following the event.

On September 6, 2022 Synaffix B.V. (Synaffix) and Emergence Therapeutics AG ("Emergence") ("the Companies") reported that the Companies have entered into a licensing agreement of up to $360 million, providing Emergence access on a target-specific basis to Synaffix’s proprietary antibody drug conjugate (ADC) technologies comprising GlycoConnect, HydraSpace and SYNtecan E linker-payload (Press release, Synaffix, SEP 6, 2022, View Source [SID1234619018]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Synaffix will be eligible to receive up to $360 million in upfront and milestone payments plus royalties on commercial sales. The first program will commence at signature, with the option to expand the collaboration to additional targets. The agreement is the result of positive proof of concept data following a successful initial discovery research collaboration between the companies.

Emergence will be responsible for the research, development, manufacturing and commercialization of the ADCs. Synaffix will be responsible for the manufacturing of components that are specifically related to its proprietary technologies.

Jack Elands, Chief Executive Officer of Emergence Therapeutics, commented: "This transaction demonstrates our commitment to the development of our pipeline of first-in-class and/or best-in-class ADCs. Beyond our lead program ETx-22, a next generation Nectin-4 ADC, we are actively advancing further programs to develop treatments for high unmet-need cancers. We are impressed with the Synaffix technology and are pleased to select it as a key component to accelerate our pipeline of ADCs."

Peter van de Sande, Chief Executive Officer of Synaffix, said: "This marks an important milestone for Synaffix as this is the 10th ADC developer who has licensed our innovative ADC technology to develop proprietary ADCs for their own pipeline. By consolidating all essential technologies within Synaffix, we have repeatedly enabled the development of best-in-class and first-in-class ADCs under a single technology license agreement. We are thrilled that Emergence has selected Synaffix as its long-term ADC technology partner and look forward to working closely with Emergence as they build out their portfolio of ADC candidates."